GlassScriptPhysician profile
Megan Payne
NPI 1134622095
$19,059.73
in general payments reported to CMS, 2019-2025
23 companies · $2,309 in 2025
The $2,309 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,354 · 2022: $4,012 · 2023: $8,976 · 2024: $2,409 · 2025: $2,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,450 · Consulting Fee: $4,145 · Travel and Lodging: $962 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,449.84 |
| Consulting Fee | $4,145.00 |
| Travel and Lodging | $962.24 |
| Education | $136.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $5,088.20 | 2023-2024 | Zoryve |
| Janssen Biotech, INC. | $3,555.89 | 2021-2025 | Tremfya, Simponi, Stelara |
| Abbvie INC. | $2,098.06 | 2021-2025 | |
| Incyte Corporation | $1,626.57 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $1,332.03 | 2021-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $1,083.47 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Regeneron Healthcare Solutions, INC. | $829.97 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $690.66 | 2021-2025 | Nemluvio, Epsolay, Aklief |
| Leo Pharma INC. | $436.72 | 2021-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $405.58 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $382.94 | 2021-2025 | |
| Ucb, INC. | $350.69 | 2022-2025 | Bimzelx, Cimzia |
| Dermavant Sciences, INC. | $283.84 | 2023-2024 | Vtama |
| Epi Health, LLC | $191.60 | 2022 | |
| Botanix Sb INC | $139.12 | 2025 | Sofdra |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $134.88 | 2022-2024 | Otezla |
| Pfizer INC. | $129.26 | 2022-2025 | |
| Almirall LLC | $102.02 | 2021-2023 | Seysara |
| Journey Medical Corporation | $54.94 | 2022-2023 | |
| Organon LLC | $44.96 | 2025 | |
| Lilly USA, LLC | $42.06 | 2023-2024 | Taltz, Ebglyss, Olumiant |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.61 | 2022-2023 | Arazlo |
| Biofrontera INC. | $15.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.